The CIIL is proud to announce that a new anti-tuberculosis concept, originally discovered by one of its team (RMB) and U1177, is tested for the first time in human. Tuberculosis remains the first cause of death due to a bacterial pathogen. Treatments are massively complicated by the continuous rise of antibiotic resistance. Molecule BVL-GSK098 reprogramming bacterial transcription to revert resistance and increase ethionamide activity has been developed by a consortium of academic teams (CIIL-U1177) and biopharmaceutical companies (BioVersys-GSK). We congratulate Alain Baulard (CIIL) and Nicolas Willand (U1177), for this exceptional accomplishment, and we wish the very best to BVL-GSK098 in its objective to save many human lives.